An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

The FDA approved Opdualag on the strength of the ... BMS' notoriously hard to tolerate CTLA4 checkpoint inhibitor – which has been approved as a monotherapy for melanoma since 2011 and as ...

The U.S. Food and Drug Administration said on Tuesday it has approved SpringWorks Therapeutics' drug to treat a type of rare ...

would be the first PD-1/PD-L1 checkpoint inhibitor to be approved for SCAC, providing Incyte with a niche indication to grow the drug without competition. That will be important, as retifanlimab ...

SinoCellTech (SHA: 688520) has received regulatory approval in China for finotonlimab, making it the first immuno-oncology ...

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

progressing on checkpoint inhibitors (QUILT-3.055): Anticipated BLA submission in 2025 with ongoing randomized Phase 3 trial in NSCLC patients who have failed checkpoint inhibitors (ResQ201A-NSCLC ...

Ellipses Pharma Limited ("Ellipses"), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it is ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...